OnCo
ideasIdea

Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer

If two drugs extend life equally but one makes patients much sicker, the health system should pay less for the sicker one. Build that into how prices are set.

Health technology assessment uses quality-adjusted life-years in principle, but in oncology practice utilities are poorly measured and toxicity rarely moves the price. The proposal is an explicit tolerability adjustment in pricing and reimbursement: standardised patient-reported tolerability data from trials feed a published formula that discounts the price for excess symptomatic toxicity and time toxicity relative to comparators, with the discount revisited as real-world PRO data accrue.

Hypothesis
A transparent toxicity price adjustment shifts industry investment toward better-tolerated agents and dosing within one product cycle, measurable as declining grade 3+ and PRO-CTCAE severe rates in newly approved drugs.
Rationale
Manufacturers respond to price signals more reliably than to guidance; today the signal on toxicity is close to zero.
What would test it
A national payer publishes and applies the adjustment for two years; compare submitted tolerability data quality and pipeline dose-optimisation activity against payers without it.
Maturity
speculative
Who has to act
payer
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks
  • Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
  • Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.

Connected

2top

Pages like this

not linked directly; found by shared links

bottlenecks

2
Prices and valueToxicity and quality of life are undervalued